{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:07:47Z","timestamp":1770415667858,"version":"3.49.0"},"reference-count":33,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Introduction: This review specifically focuses on interventional clinical trials in leukemias and myelodysplastic syndromes (MDS), summarizing how patient-reported outcome measures (PROMs) have been implemented to evaluate treatment effects rather than to directly influence clinical outcomes. Objective: Clinical outcomes of interest typically include response rates, disease-free survival (DFS), and overall survival (OS). Patient-reported outcome measures (PROMs) are standardized questionnaires that collect information regarding health outcomes directly from the patient and are used to evaluate new treatments and healthcare quality. In addition, the use of PROMs in cancer care has been shown to improve patient-provider communication and patient satisfaction. Material and Methods: This is a qualitative, narrative synthesis and review structured around PROMs focused on six critical themes: symptoms\/symptom burden, physical, emotional, social\/role, and functional status, and global health status measurement. Results: PROMs that are assessed in oncologic research include the EORTC QLQ-C30, FACT-Leu, QLQ-CLL16, and EQ-5D. PROs are associated with clinical outcomes such as DFS and OS, and the FACT-Leu scales, HRQOL and physical functioning scores were independent prognosticators of OS in patients with AML. Conclusions: Through our review, notable trends were identified that further highlight the importance of greater incorporation of PRO measures in future clinical trials, particularly in the understudied realm of hematologic malignancies, in order to better delineate the link between survival and HRQOL.<\/jats:p>","DOI":"10.3390\/hematolrep18010015","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:05:47Z","timestamp":1770372347000},"page":"15","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Review of Patient-Reported Outcomes and Clinical Outcomes in Acute and Chronic Myeloid and Lymphoid Leukemias"],"prefix":"10.3390","volume":"18","author":[{"given":"Bryan","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Harbor-UCLA Medical Center, Torrance, CA 90502, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9145-0714","authenticated-orcid":false,"given":"Eesha","family":"Balar","sequence":"additional","affiliation":[{"name":"Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2442-576X","authenticated-orcid":false,"given":"Seiichi","family":"Villalona","sequence":"additional","affiliation":[{"name":"Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4754-127X","authenticated-orcid":false,"given":"Judith","family":"Karp","sequence":"additional","affiliation":[{"name":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1368-4064","authenticated-orcid":false,"given":"Allison","family":"Leahy","sequence":"additional","affiliation":[{"name":"Center for Childhood Cancer Research, Children\u2019s Hospital of Philadelphia, Philadelphia, PA 19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Lai","sequence":"additional","affiliation":[{"name":"Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41375-019-0563-0","article-title":"Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy","volume":"34","author":"Efficace","year":"2020","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2022.10.026","article-title":"Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer","volume":"178","author":"Cocks","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/0284186X.2016.1205217","article-title":"Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL","volume":"55","author":"Hillmen","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jgo.2021.09.007","article-title":"Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemia","volume":"13","author":"Peipert","year":"2022","journal-title":"J. Geriatr. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"c186","DOI":"10.1136\/bmj.c186","article-title":"The routine use of patient-reported outcome measures in healthcare settings","volume":"340","author":"Dawson","year":"2010","journal-title":"BMJ"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/ajh.26260","article-title":"Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized phase 3 CLL14 trial","volume":"96","author":"Gentile","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1179\/2047480615Z.000000000329","article-title":"Writing narrative style literature reviews","volume":"24","author":"Ferrari","year":"2015","journal-title":"Med. Writ."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cncr.31317","article-title":"Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed or refractory acute lymphoblastic leukemia","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","article-title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia: A global single-arm phase 2 trial","volume":"20","author":"Laetsch","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00432-019-02894-3","article-title":"Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia","volume":"145","author":"Cortes","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clml.2021.09.008","article-title":"Improvements in health-related quality of life and symptoms in patients with previously untreated chronic lymphocytic leukemia: Final results from the phase II GIBB study of obinutuzumab and bendamustine","volume":"22","author":"Danilov","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","article-title":"Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome ineligible for intensive chemotherapy: Final results of a randomized phase III study","volume":"29","author":"Suciu","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1182\/bloodadvances.2021004649","article-title":"Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide versus chemotherapy","volume":"5","author":"Efficace","year":"2021","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00277-013-1686-4","article-title":"High response rate and improved exercise capacity and quality of life with darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: A phase II study by the GFM","volume":"92","author":"Kelaidi","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00277-018-3295-8","article-title":"Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: The DASPERSE study","volume":"97","author":"Kim","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1080\/03007995.2023.2262381","article-title":"Health-related quality of life in treatment-naive CLL\/SLL patients treated with zanubrutinib versus bendamustine plus rituximab","volume":"39","author":"Ghia","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.clml.2017.12.004","article-title":"Effect of lenalidomide on health-related quality of life in patients with lower-risk non\u2013del(5q) myelodysplastic syndromes: Results from the MDS-005 study","volume":"18","author":"Santini","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1200\/JCO.22.02699","article-title":"Eltrombopag for low-risk myelodysplastic syndromes with thrombocytopenia: Interim results of a phase II randomized placebo-controlled clinical trial (EQOL-MDS)","volume":"41","author":"Oliva","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1200\/JOP.19.00329","article-title":"Prognostic significance of patient-reported outcomes in cancer","volume":"16","author":"Kerrigan","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jnci\/djab087","article-title":"Patient-reported outcomes in pediatric cancer registration trials: A US Food and Drug Administration perspective","volume":"114","author":"Murugappan","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/09540261.2013.875891","article-title":"The biology of depression in cancer and the relationship between depression and cancer progression","volume":"26","author":"Sotelo","year":"2014","journal-title":"Int. Rev. Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrclinonc.2017.153","article-title":"Patient-reported outcomes in cancer care\u2014Hearing the patient voice at greater volume","volume":"14","author":"LeBlanc","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3390\/curroncol31020068","article-title":"Interventions to mitigate financial toxicity in adult patients with cancer in the United States: A scoping review","volume":"31","author":"Villalona","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12955-019-1220-z","article-title":"The impact of patient-reported outcome data from clinical trials: A systematic review and critical analysis","volume":"17","author":"Rivera","year":"2019","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1057\/s41599-023-01502-7","article-title":"The role of social capital in subjective quality of life","volume":"10","author":"Managi","year":"2023","journal-title":"Humanit. Soc. Sci. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1177\/0269216311432897","article-title":"Using observation as a data collection method to help understand patient and professional roles and actions in palliative care settings","volume":"26","author":"Walshe","year":"2012","journal-title":"Palliat. Med."},{"key":"ref_29","first-page":"1021","article-title":"Psychosocial well-being and supportive care needs of cancer patients and survivors living in rural or regional areas: A systematic review from 2010 to 2021","volume":"30","author":"Butow","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00277-023-05394-0","article-title":"Step-in dosing of bosutinib in patients with chronic phase chronic myeloid leukemia after second-generation tyrosine kinase inhibitor therapy: Results of the bosutinib dose optimization study","volume":"102","author":"Isfort","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.critrevonc.2015.07.012","article-title":"Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?","volume":"96","author":"Cannella","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Gao, P., Bai, P., Kong, X., Fang, Y., Gao, J., and Wang, J. (2022). Patient-reported outcomes and complications following breast reconstruction: Comparison between biological matrix-assisted direct-to-implant and latissimus dorsi flap. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.766076"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/1\/15\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:46:02Z","timestamp":1770374762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/1\/15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["hematolrep18010015"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18010015","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]}}}